文献速递神经肿瘤

岛叶胶质瘤最大安全切除:500例手术结局更新

Maximum safe resection of insular gliomas: update on surgical outcomes from 500 cases.
PubMed 文献 · J Neurosurg · 2026-05-08

该单中心回顾性研究纳入1997年至2022年间502例新诊断或复发岛叶胶质瘤(394例患者),采用经皮质入路结合皮层及皮层下刺激定位行最大安全切除。结果显示围手术期永久性运动或语言障碍发生率低,新诊断2级肿瘤残留体积<2.7 cm3及新诊断IDH野生型胶质母细胞瘤增强肿瘤切除率>88.6%与生存改善相关。

要点

  • 经皮质入路结合电刺激定位对岛叶胶质瘤可实现最大安全切除,手术并发症<3%。
  • 新诊断2级岛叶胶质瘤残留体积<2.7 cm3与总生存改善相关。
  • 新诊断IDH野生型胶质母细胞瘤增强肿瘤切除率>88.6%与无进展生存和总生存改善相关。

核心结论

  • 采用经皮质入路结合皮层和皮层下定位的最大安全切除,对新诊断和复发岛叶胶质瘤仍是手术并发症低的稳健策略。

研究设计与样本

  • 肿瘤按Berger-Sanai分区分类,MRI手动分割增强和非增强肿瘤体积计算切除程度。
  • 从初诊至至少6个月随访多个时间点评估患者并发症,采用未调整和倾向评分调整的Kaplan-Meier及Cox回归比较亚组间无进展生存和总生存。

主要发现

  • 纳入316例新诊断(165例低级别、151例高级别)和186例复发(69例低级别、117例高级别)病例。
  • 2级胶质瘤通常大于4级IDH野生型胶质瘤(43 cm3 vs 17.5 cm3,p < 0.001)。
  • 新诊断2级肿瘤病例中永久性术后运动和语言障碍发生率<4%,但暂时性障碍更常见(暂时性运动障碍9.5%,暂时性语言障碍20%)。
  • 新诊断2级岛叶胶质瘤残留肿瘤体积<2.7 cm3时总生存改善;复发2级岛叶胶质瘤最小化残留体积也与无进展生存和总生存延长相关。
  • 新诊断IDH野生型胶质母细胞瘤增强肿瘤切除程度>88.6%与无进展生存和总生存改善相关;手术和内科并发症总体发生率<3%。

临床怎么用

  • 对岛叶胶质瘤采用经皮质入路结合皮层和皮层下刺激定位行最大安全切除,可维持低手术并发症。
  • 新诊断2级岛叶胶质瘤手术目标可参考残留体积<2.7 cm3以改善总生存。
  • 新诊断IDH野生型胶质母细胞瘤增强肿瘤切除程度>88.6%与生存改善相关,可作为手术目标参考。
  • 新发永久性运动无力与更差总生存相关,术中应重点保护运动功能。

局限性

  • 本研究为单中心回顾性分析,证据等级受设计限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Insular gliomas present a unique surgical challenge due to their location near critical vascular structures and proximity to functional brain regions. While different surgical approaches to insular tumors exist, language and motor stimulation mapping are critical for a transcortical approach. The aim of this study was to determine if the transcortical approach to resection of insular gliomas remains a safe and effective strategy by assessing tumor characteristics, surgical outcomes, and postoperative functional outcomes in patients with newly diagnosed or recurrent tumors. METHODS: This retrospective analysis included 502 newly diagnosed and recurrent low-grade gliomas (LGGs) and high-grade gliomas (HGGs) of the insula (in 394 unique patients) resected between September 1997 and December 2022 at a single center. Tumors were classified based on the Berger-Sanai zone schema, and contrast-enhancing and non-contrast-enhancing tumor volumes were manually segmented on MRI and used to calculate the extent of resection (EOR). Patient morbidity was assessed at multiple time points from the initial presentation to at least 6 months of follow-up. Progression-free survival (PFS) and overall survival (OS) were compared between subgroups using unadjusted and propensity score-adjusted Kaplan-Meir and Cox regression analyses. RESULTS: Overall, 316 (165 LGG, 151 HGG) newly diagnosed and 186 (69 LGG, 117 HGG) recurrent cases were included. Grade 2 gliomas were typically larger than grade 4 IDH-wildtype gliomas (43 cm3 vs 17.5 cm3, p < 0.001). Persistent postoperative motor and language deficits occurred in < 4% of cases with newly diagnosed grade 2 tumors, although transient deficits occurred more frequently (9.5% of cases with transient motor deficit and 20% of cases with transient language deficit). For patients with newly diagnosed grade 2 insular gliomas, OS was improved when the residual tumor volume was < 2.7 cm3. Minimizing residual tumor volume was also associated with prolonged PFS and OS for recurrent grade 2 insular gliomas. Similarly, contrast-enhancing tumor EOR > 88.6% was associated with improved PFS and OS for patients with newly diagnosed IDH-wildtype glioblastoma. Overall, surgical and medical complications occurred in < 3% of cases. Finally, new permanent arm or leg weakness was significantly associated with worse OS in multivariable analyses (HR 2.06, 95% CI 1.14-3.74; p = 0.017). CONCLUSIONS: Maximum safe resection using a transcortical approach and cortical and subcortical mapping continues to be a robust surgical strategy with low surgical morbidity for patients with newly diagnosed and recurrent insular gliomas.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Young JS, Al-Adli NN, Quintana D, et al. Maximum safe resection of insular gliomas: update on surgical outcomes from 500 cases. J Neurosurg. 2026. PMID: 42102401. doi:10.3171/2025.12.JNS251889

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。